Clearmind Medicine Inc.
Clinical-stage psychedelic pharma firm developing treatments for Alcohol Use Disorder.
CMND | US
Overview
Corporate Details
- ISIN(s):
- CA1850534027
- LEI:
- Country:
- United States of America
- Address:
- 101-1220 WEST 6TH AVENUE, VANCOUVER, BRITISH COLUMBIA
- Sector:
- Manufacturing
Description
Clearmind Medicine Inc. is a clinical-stage psychedelic pharmaceutical company focused on developing novel psychedelic-derived therapeutics for under-served health problems. The company's primary objective is the research and development of treatments for binge behaviors and mental health conditions, with a lead focus on Alcohol Use Disorder (AUD). Its main therapeutic candidate, CMND-100, is based on the proprietary psychoactive molecule MEAI (5-Methoxy-2-aminoindane). MEAI is designed to produce an alcohol-like euphoric experience while reducing the desire to consume alcohol. The company is advancing CMND-100 in a Phase I/IIa clinical trial for AUD. Clearmind's development pipeline is supported by a portfolio of 19 patent families.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Clearmind Medicine Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Clearmind Medicine Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Clearmind Medicine Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
